According to Loscocco et al., the ABCC2 rs3740066 genotype is associated with a swifter molecular response level 3 (MR3) in CML patients taking nilotinib (32). The gene discussed is ABCC2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.